Rogers Q2 net loss of $73.6 million on impairment charges; sales rise 6.5% sequentially
Rogers reported second quarter 2025 net sales of $202.8 million, up 6.5% from the prior quarter but down from $214.2 million a year earlier. A net loss of $73.6 million, or $(4.00) per diluted share, reflected $71.8 million of non-cash impairment charges, while adjusted earnings per diluted share were $0.34. The company also announced cost reduction initiatives at its curamik business, with expected charges of $12.0 million to $20.0 million.
Key points
- Q2 2025 net sales of $202.8 million, up 6.5% sequentially and down from $214.2 million in Q2 2024
- GAAP net loss of $73.6 million, or $(4.00) per diluted share, including $71.8 million of non-cash impairment charges and $4.3 million of restructuring expenses
- Adjusted EPS of $0.34, up from $0.27 in Q1 2025 and down from $0.69 in Q2 2024
- Curamik cost initiatives expected to cut costs by more than $13.0 million annually, with $12.0 million to $20.0 million of expenses; Q3 2025 net sales guidance is $200 million to $215 million
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:56 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 31, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.